BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26645151)

  • 1. Fasting plus tyrosine kinase inhibitors in cancer.
    Caffa I; Longo VD; Nencioni A
    Aging (Albany NY); 2015 Dec; 7(12):1026-7. PubMed ID: 26645151
    [No Abstract]   [Full Text] [Related]  

  • 2. [Protein tyrosine kinase inhibitors in cancer therapy].
    Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
    Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitors in cancer therapeutics: great expectations from small molecules.
    Ansar ZA; Moatter T
    J Coll Physicians Surg Pak; 2014 Jul; 24(7):453-4. PubMed ID: 25052963
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.
    Carmi C; Mor M; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2012 Dec; 84(11):1388-99. PubMed ID: 22885287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].
    Joensuu H
    Duodecim; 2012; 128(21):2261-8. PubMed ID: 23210289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.
    Zámečníkova A
    Expert Opin Drug Discov; 2014 Jan; 9(1):77-92. PubMed ID: 24294890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities and challenges in the development of kinase inhibitor therapy for cancer.
    Sawyers CL
    Genes Dev; 2003 Dec; 17(24):2998-3010. PubMed ID: 14701871
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heritable resistance to tyrosine kinase inhibitors.
    Ong ST
    Clin Adv Hematol Oncol; 2014 Jul; 12(7):454-7. PubMed ID: 25322326
    [No Abstract]   [Full Text] [Related]  

  • 10. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
    [No Abstract]   [Full Text] [Related]  

  • 11. Tyrosine kinases as targets for cancer therapy.
    Krause DS; Van Etten RA
    N Engl J Med; 2005 Jul; 353(2):172-87. PubMed ID: 16014887
    [No Abstract]   [Full Text] [Related]  

  • 12. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
    Engelman JA; Settleman J
    Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary toxicities of tyrosine kinase inhibitors.
    Peerzada MM; Spiro TP; Daw HA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor-targeted cancer therapy.
    Richter M; Zhang H
    DNA Cell Biol; 2005 May; 24(5):271-82. PubMed ID: 15869404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
    Steeghs N; Nortier JW; Gelderblom H
    Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620
    [No Abstract]   [Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.
    Tibes R; Trent J; Kurzrock R
    Annu Rev Pharmacol Toxicol; 2005; 45():357-84. PubMed ID: 15822181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib as a paradigm of targeted therapies.
    Druker BJ
    Adv Cancer Res; 2004; 91():1-30. PubMed ID: 15327887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
    Bavcar S; Argyle DJ
    Vet Comp Oncol; 2012 Sep; 10(3):163-73. PubMed ID: 22882485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid effects and anticancer treatment.
    Nozières C; Damatte-Fauchery C; Borson-Chazot F
    Ann Endocrinol (Paris); 2011 Jun; 72(3):198-202. PubMed ID: 21640332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.